Amalgamated Financial’s Procept Biorobotics PRCT Stock Holding History

Amalgamated Financial’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$39K	Buy	+1,124	New	+$27K	﹤0.01%	2531

Other funds holding PRCT

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Amalgamated Financial's PRCT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Procept Biorobotics (PRCT) in Q1 2022: 1,124 shares worth $39K. The stake represents ﹤0.01% of the portfolio and ranks #2531 among its holdings.

58 funds tracked by Wall St. Rank hold PRCT as of Q1 2022.

Amalgamated Financial held 1,124 shares of Procept Biorobotics worth $39K as of Q1 2022.
Procept Biorobotics was a new Amalgamated Financial position in Q1 2022.
Procept Biorobotics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2531 holding.
58 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.